Background: Vascular endothelial growth factor (VEGF) inhibition is known to decrease capillary density. Decreased capillary density may be the basis for VEGF inhibitor-related side-effects. We investigated whether the effects of bevacizumab on capillary density are reversible.
Bevacizumab, an mAb against the vascular endothelial growth factor (VEGF), is currently being used in the treatment of various types of cancer, including colorectal, breast, renal cell and non-small-cell lung cancers [1] [2] [3] [4] [5] [6] .
A clear decrease in capillary density has been reported in the treatment with two VEGF inhibitors, telatinib and bevacizumab [7, 8] . Decreased vascular density, or rarefaction, may be a possible mechanism for various side-effects seen in the treatment with VEGF inhibitors. One of these side-effects is hypertension, with grade 3-4 hypertension, using the common toxicity criteria, developing in 9%-16% of bevacizumab-treated patients [9, 10] . Research in rats also showed that vascular rarefaction may be the cause of sunitinib-induced hypothyroidism and bevacizumab-induced enteric perforations [11] . Since bevacizumab-treated patients may have a prognosis of several years in palliative setting and many years when adjuvant schedules will prove to be beneficial, the patient group is relatively large. Increased knowledge on bevacizumabinduced vascular changes may help to identify patients at risk for complications, stimulate the sense of urgency to monitor patients and to start early treatment in case of hypertension, hypothyroidism, encephalopathy or other vascular-related complications [12] .
The aim of this study is to investigate whether the bevacizumab-associated vascular and BP effects are reversible after discontinuation of bevacizumab treatment. An additional goal is to provide more information on the mechanisms in the development of bevacizumab-associated side-effects.
patients and methods eligibility criteria and study outline Patients receiving bevacizumab monotherapy or combination therapy for breast or colorectal cancer were eligible for participation. Patients with previous bevacizumab treatment, major surgery within the last 4 weeks or clinical significant cardiovascular disease in the previous year were excluded. Written informed consent was obtained from all patients before any studyrelated procedure was carried out, and approval from the institutional medical ethical review boards was obtained before study initiation.
BP measurements and vascular assessments were carried out at baseline (<7 days before first bevacizumab administration), after 6 weeks (before original article flow-mediated dilation. The flow-mediated dilation (FMD) measurements were done in a quiet temperature-controlled room. Postischemic vasodilator responses in the brachial artery were measured using a Wall Track System (WTS 2; Pie Medical, Maastricht, The Netherlands). This system consists of a standard 7.5-MHz linear array ultrasound transducer connected to a PC equipped with a data acquisition board and software. Subjects were investigated in a supine position, and three electrocardiogram Data are presented as n (%) unless otherwise specified. BMI, body mass index; CVD, cardiovascular disease; ULN, upper limit of normal; WHO, World Health Organization.
Annals of Oncology original article leads were attached. Ischemia was induced in the forearm by inflation of a BP cuff just below the elbow of the right arm for 5 min. After deflation of the cuff, changes in brachial artery wall diameter were measured every 20 s for 4 min. WTS measurements were stored and analyzed off line using WTS software. FMD was expressed as percentage change in brachial artery diameter after ischemia.
nitroglycerin-mediated dilation. Nitroglycerin-mediated dilation (NMD) was assessed in the same way as FMD, with the exception that 0.4 mg of nitroglycerin was given sublingually, instead of cuff inflation and deflation, before measurements were started.
aortic pulse wave velocity. Measurements were done at the right carotid and femoral arteries using standard BP transducers (SphygmoCor SCOR-PVx device; AtCor) with simultaneous electrographic gating. This enabled the base of the pressure wave to be recorded and the time delay between the carotid and femoral waves to be calculated. The distance between the two sites was measured. Aortic pulse wave velocity (PWV) was defined as the distance traveled by the pressure waves divided by the time delay.
statistical analysis
Continuous variables are presented as mean values and categorical variables as frequencies (percentages), unless otherwise stated. Comparisons between variables at baseline, after 6 weeks and after discontinuation of bevacizumab treatment were made with a general linear model repeated measures test or with a paired Student's t-test, were appropriate and were two sided, with a level of significance of a = 0.05. All calculations were made by computerassisted analyses using SPSS 16.0 (Chicago, IL) statistical package for Windows.
results
From March 2007 to July 2008, a total of 14 patients were enrolled in the study. In eight patients, measurements could be carried out after discontinuation of bevacizumab treatment. Baseline patient and treatment characteristics of both groups are listed in Table 1 .
Patients received bevacizumab for colorectal cancer (12 patients) or breast cancer (2 patients). All patients had metastasized disease. Bevacizumab dose was 7.5 mg/kg/3 weeks for the patients with colorectal cancer and 10 mg/kg/2 weeks for the breast cancer patients. Bevacizumab was combined with various chemotherapy schedules: capecitabine plus oxaliplatin (seven patients), capecitabine (three patients), irinotecan (two patients), paclitaxel and capecitabine (one patient) and paclitaxel (one patient).
reversibility of vascular changes
Measurements after discontinuation of bevacizumab treatment could be carried out in eight patients. In one of these patients, SDF data were not available due to technical reasons. original article Annals of Oncology capillary density measurements with SDF imaging. Using a general linear model repeated measures test on the seven patients with three evaluable SDF measurements, before, during and after bevacizumab treatment, the change in capillary density due to bevacizumab treatment was significant, with a P value of 0.00001 (Figure 1 ). More importantly, after discontinuation of the bevacizumab treatment, the changes in capillary density showed to be reversible, with a P value of 0.001 (Figure 1) . Figure 2 shows the SDF images of a representative patient, demonstrating visible capillary loops at baseline, decreased capillary density after 6 weeks of bevacizumab treatment and normalization of capillary density >3 months after bevacizumab discontinuation.
Of the seven patients, six patients were without any systemic anticancer therapy in the 3 months before the third visit. One patient was still treated with capecitabine plus oxaliplatin, however without bevacizumab.
At baseline, two patients received a single BP-lowering agent (thiazide diuretic or angiotensin-II receptor antagonist), three patients received two agents [b-blocker plus thiazide diuretic, b-blocker plus angiotensin-converting enzyme (ACE) inhibitor and b-blocker plus angiotensin-II receptor antagonist, all in one patient, respectively] and one patient received three BPlowering agents (b-blocker plus loop diuretic plus angiotensin-II receptor antagonist). These BP-lowering medication schedules remained unchanged for all six of the abovedescribed patients for the duration of the entire study. One additional patient, patient 14, was started on antihypertensive treatment with a calcium antagonist during bevacizumab treatment.
BP, vascular function and vascular structure assessments. With a general linear model repeated measures test, there were no significant changes in BP or vascular function and vascular structure parameters, besides FMD (Table 2) . Comparing results of visit 3 with visit 2, FMD remained unchanged after discontinuation of bevacizumab treatment.
vascular changes during bevacizumab treatment
In a total of 14 patients, measurements were carried out before and during treatment with bevacizumab.
In six patients, additional measurements after discontinuation of bevacizumab treatment could not be carried out due to various reasons: two patients died, two patients were in poor clinical condition due to tumor progression, one moved out of the region and one was still receiving bevacizumab treatment. capillary density measurements with SDF imaging. In all 14 patients, the number of capillary loops markedly decreased from 18.2 at baseline to 13.3 (P = 0.00002) after 6 weeks of treatment with bevacizumab (Table 2) .
BP, vascular function and vascular structure assessments. There was no significant change in most of the BP parameters after 6 weeks of treatment with bevacizumab (Table 2 ). There was a significant increase in peripheral diastolic BP. The decrease in FMD from 6.3% to 3.2% after 6 weeks of treatment was statistically significant (P = 0.006) when compared with baseline (Table 2 ). There was no change in NMD. Mean PWV significantly increased from 8.9 m/s at baseline to 9.6 m/s after 6 weeks of treatment (P = 0.027; Table 2 ).
association of capillary density with bevacizumab efficacy Figure 3 shows the relationship between capillary density changes and bevacizumab efficacy. Among the six patients who were alive and showed no tumor progression within 6 months of start of bevacizumab treatment were the three patients showing the clearest decrease in capillary density after 6 weeks of bevacizumab treatment.
discussion
We conducted this study to investigate whether bevacizumabassociated vascular and BP effects are reversible after discontinuation of bevacizumab treatment. We additionally aimed at providing more information on the mechanisms in the development of bevacizumab-associated side-effects. To our knowledge, this is the first study describing effects on BP and the vascular system after discontinuation of VEGFinhibitory treatment. Until now, the reversibility of vascular changes has never been documented in humans. We now report that the bevacizumab-induced decrease in capillary density is reversible. Although this study was carried out in a limited number of patients, our results are consistent and in line with previous preclinical data. Preclinical data show rapid reversibility of capillary regression after cessation of VEGF inhibition in normal organs and tumors in mice [16] [17] [18] . Strikingly, most capillaries grew back within 2 weeks after cessation of treatment.
In this journal, Mourad et al. [8] reported endothelial dysfunction and capillary rarefaction in 18 bevacizumab-treated patients. We previously reported a reduction in capillary density (rarefaction) and microvascular flow, associated with a reduced vasodilatory capacity induced by telatinib, an orally active small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor-a and c-Kit [7] . With the current study, we confirm that treatment with bevacizumab results in a clear decrease in capillary density. And, after studying both a smallmolecule tyrosine kinase inhibitor of VEGFR and an mAb against VEGF, we conclude that the induced decrease in capillary density probably represents a class effect of all VEGF inhibitors. In this study, there was a significant decrease in capillary density after 6 weeks of bevacizumab treatment; however, there was no significant increase in BP. This might be explained by the timing of the measurements, i.e. after 6 weeks or two half-lives of bevacizumab. The decrease in capillary density may be induced before an increase in BP develops. Other explanations may be the limited number of patients or the use of BP-lowering agents in almost half of the patients.
We designed our study such that our data can be extrapolated to the general patient population treated with bevacizumab-containing anticancer treatment. To maximally imitate daily life, we decided not to exclude patients using BP-lowering agents at baseline. While multiple measurements were carried out in the same patients and patients therefore were their own internal control, this resulted in accurate statistical data. We also decided to include patients receiving bevacizumab in combination with various cytotoxic agents. Since vascular changes were seen in all patients, we can conclude that the changes in vascular parameters are linked to the bevacizumab treatment and are irrespective of the cytotoxic agents used in the bevacizumab combination.
The SDF method is a very elegant method for measuring capillary density. It is a noninvasive not painful method, with no side-effects for the test subject. Measurements can be carried out in almost all subjects, and the mucosal surface of the inner lip is intact and easy to reach in most patients. Moreover, the measurement time for the patient is limited, and large parts of the data analysis can be carried out off line. The technique is fairly easy to learn, and reproducibility of data is generally high [7, 13, 14] .
Our results may have several implications in the treatment of cancer patients with VEGF inhibitors. Recently, increased BP during treatment with VEGF inhibitors has been associated with a longer time to tumor progression [19] [20] [21] [22] . Possibly, capillary density measured by the noninvasive SDF method can be used as an even earlier marker for response. In our study, we could show that decreased capillary density during bevacizumab treatment may be associated with a better prognosis. However, this is exploratory and confirmation with adequate sample size is needed. Also, theoretically, combining capillary density measurements with BP changes can result in a better predictive marker than BP alone. Moreover, we would like to stimulate the sense of urgency to monitor patients since the reversibility of vascular changes after discontinuation of VEGF-inhibiting therapy might indicate that timely intervention may reduce or prevent certain side-effects with sometimes high morbidity and even mortality. This is the first study reporting that the bevacizumabinduced capillary density decrease is reversible after discontinuation of bevacizumab treatment. In combination with earlier results in VEGF tyrosine kinase inhibitor treatment, we also report that VEGF-associated rarefaction is a class effect generated by all VEGF inhibitors.
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